AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. raised its position in shares of AstraZeneca PLC (NASDAQ:AZNFree Report) by 13.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 115,428 shares of the company’s stock after purchasing an additional 13,311 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in AstraZeneca were worth $7,774,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Anchor Investment Management LLC bought a new position in AstraZeneca in the 4th quarter worth approximately $26,000. Compagnie Lombard Odier SCmA acquired a new position in shares of AstraZeneca during the fourth quarter valued at $27,000. Nemes Rush Group LLC raised its stake in shares of AstraZeneca by 375.6% during the third quarter. Nemes Rush Group LLC now owns 428 shares of the company’s stock valued at $29,000 after purchasing an additional 338 shares in the last quarter. Northwest Financial Advisors bought a new stake in shares of AstraZeneca during the fourth quarter valued at about $34,000. Finally, LWM Advisory Services LLC acquired a new stake in AstraZeneca in the third quarter worth about $35,000. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of NASDAQ AZN traded up $0.16 during midday trading on Monday, reaching $77.34. The company’s stock had a trading volume of 1,683,512 shares, compared to its average volume of 6,237,920. AstraZeneca PLC has a one year low of $60.47 and a one year high of $77.93. The company has a market cap of $239.79 billion, a price-to-earnings ratio of 37.90, a price-to-earnings-growth ratio of 1.40 and a beta of 0.47. The company has a 50 day moving average price of $69.53 and a 200 day moving average price of $66.79. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73.

AstraZeneca (NASDAQ:AZNGet Free Report) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.73 EPS for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). The company had revenue of $12.02 billion for the quarter, compared to analyst estimates of $12.07 billion. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. AstraZeneca’s revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the company posted $0.69 EPS. On average, equities research analysts expect that AstraZeneca PLC will post 4.03 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on AZN. BMO Capital Markets boosted their price target on shares of AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, April 26th. Morgan Stanley assumed coverage on AstraZeneca in a report on Tuesday, January 23rd. They set an “overweight” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $81.00.

Read Our Latest Research Report on AZN

AstraZeneca Company Profile

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Recommended Stories

Want to see what other hedge funds are holding AZN? Visit to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNFree Report).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.